from Laura White and G. Eric Blair writing in Small DNA Tumour Viruses:
Adenovirus (Ad)-based vectors have been frequently used as gene therapy vectors due to their ability to infect a wide range of dividing and non-dividing cells, their efficient growth to high titres in complementing cell lines and ease of genome manipulation. However, the transition of Ad vectors from in vitro studies to clinical application has been limited by sub-optimal efficacy and robust inflammatory responses elicited upon administration. In recent years it has become clear that multiple innate and adaptive responses limit the efficacy and safety of Ad vectors. In this review, we focus on the current understanding of the immune response to Ads with a particular focus on the innate immune response, and how this information can be used to design safer and more efficacious vectors.
Further reading: Small DNA Tumour Viruses Related publications